Navigation Links
MacuCLEAR, Inc. to Present at OneMedForum New York 2011 and at the 2011 BIO Business Forum During the Annual BIO International Convention in Washington, D.C.
Date:6/16/2011

PLANO, Texas, June 16, 2011 /PRNewswire/ -- MacuCLEAR, Inc., a specialty clinical stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today that Philip G. Ralston, president and CEO, will be presenting at OneMedForum New York 2011 on Thursday, June 23, 2011 at 11:30 a.m. EDT at The Roosevelt Hotel in New York City.  

OneMedForum will focus on critical success factors for building companies internationally.  In addition to presentations by more than 70 emerging medical technology companies, delegates will gain insights in the critical areas of regulatory approval, reimbursement and distribution and sales organizations in the EU and U.S.

Concurrently, Mr. Ralston will also present at the 2011 BIO Business Forum during the annual BIO International Convention at the Walter E. Washington Convention Center in Washington, D.C.  Mr. Ralston's presentation will be given on Wednesday, June 29, 2011 at 9:15 a.m. EDT in the Adams Morgan Room.  The presentation will include an overview of the company with emphasis on the lead proprietary compound, MC-1101, which is being developed for the treatment of the dry form of age-related macular degeneration (AMD).

The BIO Business Forum is a unique platform for biotechnology and pharmaceutical companies, academic research institutions and investors from around the world to gather and discuss strategic opportunities.  This forum is featured within the BIO International Convention, the largest global event for the biotechnology industry, offering networking and partnering opportunities with policymakers, scientists, CEOs and newsmakers and hundreds of sessions covering biotech trends, policy issues and technological innovations.

About MacuCLEAR, Inc.

MacuCLEAR, Inc. is a clinical-stage specialty pharmaceutical company focused on developing innovative treatments for vascular and retinal diseases of the eye.  Its lead compound MC-1101 is a novel, topically delivered eye drop drug for treating and stopping the progression of age-related macular degeneration (AMD) from the early-stage (Dry AMD) to the late-stage (Wet AMD) by improving ocular blood flow.

The active ingredient of MC-1101 has been previously approved by the FDA as an oral antihypertensive drug.  MC-1101 has been granted 505 (b) 2 status and has formal Fast Track designation by the FDA.  In addition to MC-1101, MacuCLEAR's portfolio includes 11 compounds that are being developed for diabetic retinopathy, second-generation treatment for AMD and other vascular diseases of the eye.

George C.Y. Chiou, Ph.D., who led the development of Timolol, a pioneering treatment for glaucoma, invented this technology at Texas A&M University.

Founded in 2006, MacuCLEAR is a privately held Plano, TX-based company.  For additional information, please visit www.macuclear.com.

About Age-Related Macular Degeneration

AMD is the leading cause for blindness in the world in people 50 and older.  Dry AMD afflicts 90 percent of AMD sufferers and currently has no approved drug treatments.  

Media Contact:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach, amielach@tiberend.com
or
Claire Sojda, csojda@tiberend.com


'/>"/>
SOURCE MacuCLEAR, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use
2. NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society
3. Dendreon Announces Webcast Presentation at NASDAQ OMX 26th Investor Program
4. NeoStem to Present at Two Investor Events This Month
5. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
6. Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings
7. PAREXEL International to Present at Wells Fargo Healthcare Conference
8. Spherix to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
9. Sono-Tek to Present Scientific Paper on Food Safety at the IFT, as E. Coli Outbreak Affects Europes Food Supply
10. Masimo to Present at William Blair & Company 31st Annual Growth Stock Conference
11. IDEXX Laboratories to Present at William Blair 31st Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative ... range of emerging technology-based businesses, recently earned a $77,518 grant from the Rural ... Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI is ...
(Date:4/20/2017)... ... April 20, 2017 , ... Assured Enterprises, Inc. ... a full spectrum of digital security goods and services. The strategic partners now ... ground-breaking proactive cybersecurity services and products through Assured Enterprises. The two companies provide ...
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences , the ... and healthcare industries, is pleased to announce Holger Braemer as Vice President ... Europe GmbH” based in Germany. , Braemer is an integral part of USDM’s ...
(Date:4/20/2017)... ... ... NetDimensions appoints Bill Mastin, a learning technology veteran, as its new Senior Vice ... technologies industry, Mastin joins NetDimensions from the New York office of learning and engagement ... served as SVP of the North America offices and prior to that, he held ...
Breaking Biology Technology:
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
Breaking Biology News(10 mins):